Two novel ocular hypotensive agents that have just been approved for use in humans — netarsudil and latanoprostene bunod (LBN) — greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans. Two articles that highlight these two breakthrough drugs, as well as cutting-edge articles on the effects of amitriptyline… Continue reading New Glaucoma Drugs Yield Large, Lasting Reductions in Intraocular Pressure